BE2024C511I2 - - Google Patents

Download PDF

Info

Publication number
BE2024C511I2
BE2024C511I2 BE2024C511C BE2024C511C BE2024C511I2 BE 2024C511 I2 BE2024C511 I2 BE 2024C511I2 BE 2024C511 C BE2024C511 C BE 2024C511C BE 2024C511 C BE2024C511 C BE 2024C511C BE 2024C511 I2 BE2024C511 I2 BE 2024C511I2
Authority
BE
Belgium
Application number
BE2024C511C
Other languages
Dutch (nl)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2024C511(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BE2024C511I2 publication Critical patent/BE2024C511I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2024C511C 2004-05-20 2024-03-15 BE2024C511I2 (enEXAMPLES)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
BE2024C511I2 true BE2024C511I2 (enEXAMPLES) 2024-10-08

Family

ID=35079161

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2024C511C BE2024C511I2 (enEXAMPLES) 2004-05-20 2024-03-15

Country Status (33)

Country Link
US (7) US7635704B2 (enEXAMPLES)
EP (4) EP3281939B1 (enEXAMPLES)
JP (1) JP3754064B2 (enEXAMPLES)
KR (1) KR20080064909A (enEXAMPLES)
CN (1) CN1956961B (enEXAMPLES)
AR (2) AR049280A1 (enEXAMPLES)
AU (1) AU2005245296B2 (enEXAMPLES)
BE (1) BE2024C511I2 (enEXAMPLES)
BR (1) BRPI0510114B8 (enEXAMPLES)
CA (1) CA2566922C (enEXAMPLES)
CY (4) CY1113010T1 (enEXAMPLES)
DK (2) DK1636190T3 (enEXAMPLES)
ES (2) ES2960824T3 (enEXAMPLES)
FI (2) FI3281939T3 (enEXAMPLES)
FR (1) FR23C1040I1 (enEXAMPLES)
HR (2) HRP20120681T1 (enEXAMPLES)
HU (2) HUE064615T2 (enEXAMPLES)
IL (1) IL179250A0 (enEXAMPLES)
LT (1) LT3281939T (enEXAMPLES)
LU (1) LUC00334I2 (enEXAMPLES)
MX (1) MXPA06013405A (enEXAMPLES)
MY (1) MY134672A (enEXAMPLES)
NO (8) NO339223B1 (enEXAMPLES)
NZ (1) NZ551839A (enEXAMPLES)
PE (2) PE20060358A1 (enEXAMPLES)
PL (2) PL3281939T3 (enEXAMPLES)
PT (2) PT1636190E (enEXAMPLES)
RS (2) RS52375B (enEXAMPLES)
RU (1) RU2330845C1 (enEXAMPLES)
SI (2) SI1636190T1 (enEXAMPLES)
TW (1) TWI329015B (enEXAMPLES)
WO (1) WO2005113508A1 (enEXAMPLES)
ZA (1) ZA200610647B (enEXAMPLES)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
AU2003302029B8 (en) * 2002-11-20 2006-08-17 Japan Tobacco Inc. 4-oxoquinoline compound and utilization thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EA201201496A1 (ru) * 2005-12-30 2013-07-30 Джилид Сайэнс, Инк. Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
EA017861B9 (ru) * 2006-03-06 2014-05-30 Джапан Тобакко Инк. Способ получения 4-оксохинолинового соединения
IN2014CN00532A (enEXAMPLES) 2006-03-06 2015-04-03 Japan Tobacco Inc
CN101490023B (zh) 2006-07-07 2013-05-29 吉里德科学公司 治疗剂的药代动力学特性调节剂
EP2644587A3 (en) 2006-09-12 2013-10-23 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
LT2487162T (lt) * 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
CA2692101A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
MX2009013828A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Composiciones terapeuticas y su uso.
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
CN102123700A (zh) 2008-05-02 2011-07-13 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
PT2393485E (pt) 2009-02-06 2015-10-23 Gilead Sciences Inc Comprimidos bicamada que compreendem elvitegravir, cobicistat, emtricitabina e tenofovir
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
CN104520275B (zh) 2012-08-03 2016-11-02 吉利德科学公司 用于制备整合酶抑制剂的方法和中间产物
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
NO2865735T3 (enEXAMPLES) 2013-07-12 2018-07-21
WO2015006731A1 (en) 2013-07-12 2015-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
NO2717902T3 (enEXAMPLES) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
NZ735575A (en) 2015-04-02 2018-11-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (enEXAMPLES) 1970-09-14 1981-02-16
JPS4826772A (enEXAMPLES) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
CN1152916A (zh) 1994-07-18 1997-06-25 宇部兴产株式会社 三氟甲基喹啉羧酸衍生物
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
PT892801E (pt) 1996-04-12 2002-06-28 Us Gov Health & Human Serv Compostos derivados de acridona uteis como agentes antineoplasicos e antiretrovirais
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
ATE345129T1 (de) 2000-10-12 2006-12-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
BR0207809A (pt) 2001-03-01 2004-03-09 Shionogi & Co Compostos heteroarila contendo nitrogênio possuindo atividade inibidora contra integrase de hiv
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
AU2003302029B8 (en) * 2002-11-20 2006-08-17 Japan Tobacco Inc. 4-oxoquinoline compound and utilization thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
JP4629104B2 (ja) 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤

Also Published As

Publication number Publication date
NO20190051A1 (no) 2007-02-07
WO2005113508A1 (en) 2005-12-01
IL179250A0 (en) 2007-03-08
JP2006001927A (ja) 2006-01-05
US20100204271A1 (en) 2010-08-12
PL1636190T3 (pl) 2012-10-31
SI1636190T1 (sl) 2012-09-28
HUS2400006I1 (hu) 2024-04-28
EP4299563A3 (en) 2024-02-28
EP1636190B1 (en) 2012-06-27
NO20161297A1 (no) 2007-02-07
EP4299563A2 (en) 2024-01-03
PE20060358A1 (es) 2006-05-12
CN1956961A (zh) 2007-05-02
US8981103B2 (en) 2015-03-17
MY134672A (en) 2007-12-31
HRP20231588T3 (hr) 2024-03-15
RU2330845C1 (ru) 2008-08-10
FIC20240008I1 (fi) 2024-03-20
EP3281939A1 (en) 2018-02-14
NO2024034I1 (no) 2024-07-15
CY2015009I2 (el) 2024-09-20
LT3281939T (lt) 2023-11-27
ES2388441T3 (es) 2012-10-15
EP3281939B1 (en) 2023-10-18
CY2024008I1 (el) 2024-09-20
CA2566922A1 (en) 2005-12-01
US20190185433A1 (en) 2019-06-20
US20180029989A1 (en) 2018-02-01
BRPI0510114A (pt) 2007-09-25
KR20080064909A (ko) 2008-07-09
CY1113010T1 (el) 2016-04-13
HUE064615T2 (hu) 2024-04-28
NO20230913A1 (no) 2007-02-07
TW200600097A (en) 2006-01-01
RS52375B (en) 2012-12-31
BRPI0510114B8 (pt) 2021-05-25
AR049280A1 (es) 2006-07-12
PT1636190E (pt) 2012-08-20
DK1636190T3 (da) 2012-09-24
AU2005245296B2 (en) 2010-08-12
AU2005245296A1 (en) 2005-12-01
NZ551839A (en) 2009-11-27
ES2960824T3 (es) 2024-03-06
CY1126560T1 (el) 2024-09-20
CY2024008I2 (el) 2024-09-20
AR096100A2 (es) 2015-12-09
NO20220690A1 (no) 2007-02-07
NO339223B1 (no) 2016-11-21
US20060030710A1 (en) 2006-02-09
NO347902B1 (no) 2024-05-06
PE20120361A1 (es) 2012-05-03
NO20200873A1 (no) 2007-02-07
EP1636190A1 (en) 2006-03-22
PT3281939T (pt) 2023-11-22
CN1956961B (zh) 2010-05-26
NO20065790L (no) 2007-02-07
FI3281939T3 (fi) 2023-10-23
HRP20120681T1 (hr) 2012-09-30
RS64845B1 (sr) 2023-12-29
PL3281939T3 (pl) 2024-03-18
US20250091995A1 (en) 2025-03-20
TWI329015B (en) 2010-08-21
MXPA06013405A (es) 2007-03-01
FR23C1040I1 (fr) 2023-12-29
CY2015009I1 (el) 2024-09-20
JP3754064B2 (ja) 2006-03-08
ZA200610647B (en) 2008-06-25
US7635704B2 (en) 2009-12-22
NO20240384A1 (no) 2007-02-07
EP2514746A1 (en) 2012-10-24
CA2566922C (en) 2011-01-11
US20150361044A1 (en) 2015-12-17
BRPI0510114B1 (pt) 2020-09-15
DK3281939T3 (da) 2024-01-22
US20220235009A1 (en) 2022-07-28
SI3281939T1 (sl) 2024-02-29
HK1083341A1 (en) 2006-06-30
LUC00334I2 (enEXAMPLES) 2024-07-01

Similar Documents

Publication Publication Date Title
BE2024C511I2 (enEXAMPLES)
BE2015C041I2 (enEXAMPLES)
BE2014C063I2 (enEXAMPLES)
IN2010KO00412A (enEXAMPLES)
IN2006DE04680A (enEXAMPLES)
BRPI0515516B8 (enEXAMPLES)
ECSDI045293S (enEXAMPLES)
IN2006DE04099A (enEXAMPLES)
ECSDI055661S (enEXAMPLES)
IN2006CH03371A (enEXAMPLES)
JP2004317520A5 (enEXAMPLES)
IN2006DE07403A (enEXAMPLES)
JP2004239438A5 (enEXAMPLES)
IN2007CH00221A (enEXAMPLES)
JP2005303693A5 (enEXAMPLES)
JP2005287097A5 (enEXAMPLES)
DE602005023135D1 (enEXAMPLES)
JP1223289S (enEXAMPLES)
JP2005329361A5 (enEXAMPLES)
JP2005247034A5 (enEXAMPLES)
JP2005237174A5 (enEXAMPLES)
JP2005214105A5 (enEXAMPLES)
JP2005262469A5 (enEXAMPLES)
JP2005264861A5 (enEXAMPLES)
IN2004DE00514A (enEXAMPLES)